Objective To study the clinical efficacy of crizotinib for advanced ALK positive non-small cell lung cancer (NSCLC).Methods 60 patients with advanced ALK positive NSCLC patients were randomly divided into the control group and the experiment group ,The experimental group received crizotinib and the control group received docetaxel .Treatment effect , ad-verse reactions and survival of the 2 groups were compared .Results The effective rates of the experimental group and the control group were respectively 76.7%,and 20.0%;control rates of the 2 groups were 93.3%,60.0%,the experimental group had bet-ter efficacy and safety than the control group .Conclusion Crizotinib for advanced ALK positive NSCLC is effective ,and whether it can be a first-line therapy needs large sample clinical trials .%目的 探讨克唑替尼对治疗进展期ALK阳性非小细胞肺癌的临床治疗效果.方法 选取60例进展期ALK阳性非小细胞肺癌(NSCLC)患者,随机分为实验组和对照组,实验组和对照组患者分别应用克唑替尼和多西他赛进行治疗.对比两组治疗效果、不良反应及生存期.结果 实验组和对照组有效率分别为76.7%,20.0%;控制率分别为93.3%、60.0%,实验组较对照组具有更好的安全性和疗效.结论 克唑替尼对进展期ALK阳性非小细胞肺癌有着良好的治疗效果,其能否成为一线治疗药物,有待大样本临床试验研究.
展开▼
